Abstract
While it is well established that overall glycemic control reduces the complications of diabetes, the role of fasting glycemia versus postprandial glycemia in the pathophysiology of diabetes and its complications, and the relative importance of these parameters as specific targets of therapy, remain controversial. Evidence that postprandial glucose (PPG) plays an independent, modifiable role in cardiovascular disease is accumulating, largely from epidemiological studies. A large number of epidemiological studies show that high postprandial glucose is an independent risk factor for cardiovascular disease: indeed, a more powerful risk factor than fasting glucose or HbA1c. Pathophysiological hypotheses that support these observations include the contribution of postprandial glucose to HbA1c; postprandial glucose as a surrogate marker for other cardiovascular risk factors, serum lipids and triglycerides in particular; and direct toxicity of elevated glucose levels attributed to "spikes" in glucose concentration following caloric ingestion. Early interventional data suggest that therapy targeted at postprandial glucose can have a favorable impact on cardiovascular events. While more interventional studies clearly are needed, the growing weight of evidence supports a therapeutic approach more directed at excessive prandial glycemic excursions that are characteristic of both type 1 and type 2 diabetes.
Similar content being viewed by others
References
Harris, M., Flegal, K. M., Cowie, C. C., et al. (1998). Diabetes Care 21, 518–524.
The DECODE Study Group (2003). Diabetes Care 26, 61–69.
The DECODE Study Group (2003). Diabetes Care 26, 688–696.
DCCT Research Group (1993). N. Engl. J. Med. 329(14), 977–986.
UK Prospective Diabetes Study (UKPDS) Group (1998). Lancet 352(9131), 837–853.
DECODE Study Group (1999). Lancet 354, 617–621.
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., and Sekikawa, A. (1999). Diabetes Care 22(6), 920–924.
Balkau, B., Shipley, M., Jarrett, R. J., et al. (1998). Diabetes Care 21, 360–373.
Barrett-Connor, E. and Ferrara, A. (1998). Diabetes Care 21, 1236–1239.
Hanefeld, M., Fischer, S., Julius, U., et al. (1996). Diabetologia 39, 1577–1583.
Chiasson, J. L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., and Laakso, M.; STOP-NIDDM Trial Research Group (2003). JAMA 290, 486–494.
Monnier, L., Lapinski, H., and Colette, C. (2003). Diabetes Care 26, 881–885.
Esposito, K., Giugliano, D., Nappo, F., and Marfella, R. (2004). Circulation 110, 214–219.
Stamler, J., Vaccaro, O., Neaton, J. D., and Wentworth, D. (1993). Diabetes Care 16, 434–444.
The DECODE Study Group (2003). Diabetologia 46, 608–617.
Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K., and Laakso, M. (1998). N. Engl. J. Med. 339, 229–234.
Coutinho, M., Gerstein, H. C., Wang, Y., and Yusuf, S. (1999). Diabetes Care 22, 233–240.
Temelkova-Kurktschiev, T., Koehler, C., Henkel, E., Leonhardt, W., Fuecker, K., and Hanefeld, M. (2000). Diabetes Care 23, 1830–1834.
de Veciana, M., Major, C. A., Morgan, M. A., et al. (1995). N. Engl. J. Med. 333, 1237–1241.
Manderson, J. G., Patterson, C. C., Hadden, D. R., Traub, A. I., Ennis, C., and McCance, D. R. (2003). Am. J. Obstet. Gynecol. 189, 507–512.
Stratton, I. M., Adler, A. I., Neil, H. A. W., et al. (2000). Br. Med. J. 321(7258), 405–412.
Kuusisto, J., Mykkanen, L., Pyorala, K., and Laakso, M. (1994). Diabetes 43(8), 960–967.
DCCT Research Group (1995). Diabetes 44, 968–983.
Shichiri, M., Kishikawa, H., Ohkubo, Y., and Wake, N. (2000). Diabetes Care 23(Suppl. 2), B21-B29.
Avignon, A., Radauceanu, A., and Monnier, L. (1997). Diabetes Care 20, 1822–1826.
Bos, G., Dekker, J. M., Nijpels, G., et al. (2003). Diabetologia Jul. 46(7), 910–916 (Epub Jun. 18).
Bos, G., Dekker, J. M., and Heine, R. J. (2004). Diabetes Care 27, 283–284.
Heine, R. J. and Dekker, J. M. (2002). Diabetologia 45, 461–475.
Vogel, R. A., Corretti, M. C., and Plotnick, G. D. (1997). Am. J. Cardiol. 79, 350–354.
Ceriello, A., Taboga, C., Tonutti, L., et al. (2002). Circulation 106, 1211–1218.
de Vegt, F., Dekker, J. M., Ruhe, H. G., et al. (1999). Diabetologia 42, 926–931.
Muggeo, M., Zoppini, G., Bonora, E., et al. (2000). Diabetes Care 23(1), 45–50.
Beisswenger, P. J., Makita, Z., Curphey, T. J., et al. (1995). Diabetes 44(7), 824–829.
Beisswenger, P. J., Szwergold, B. S., and Yeo, K. T. (2001). Clin. Lab. Med. 21(1), 53–78.
Szwergold, B. S., Howell, S., and Beisswenger, P. J. (2001). Diabetes 50(9), 2139–2147.
McLellan, A. C., Thornalley, P. J., Benn, J., and Sonksen, P. H. (1994). Clin. Sci. 87, 21–29.
Beisswenger, P. J., Howell, S. K., O’Dell, R. M., Wood, M. E., Touchette, A. D., and Szwergold, B. S. (2001). Diabetes Care 24, 726–732.
Brownlee, M. (2001). Nature 414, 813–820.
Dandona, P., Mohanty, P., Ghanim, H., et al. (2001). J. Clin. Endocrinol. Metab. 86(1), 355–362.
Ceriello, A., Bortolotti, N., Motz, E., et al. (1999). Metabolism 48(12), 1503–1508.
American Diabetes Association Clinical Practice Recommendations (2003). Diabetes Care 26(Suppl. 1), S1-S1081.
DECODE Study Group (1998). Br. Med. J. 317, 371–375.
The DECODA Study Group on behalf of the International Diabetes Epidemiology Group (2000). Diabetologia 43, 1470–1475.
Holst, J. J. and Deacon, C. F. (2004). Curr. Opin. Pharmacol. 4, 589–596.
Culy, C. R. and Jarvis, B. (2001). Drugs 61, 1625–1660.
Tuomilehto, J., Lindström, J., Eriksson, J., et al. (2001). N. Engl. J. Med. 346(6), 393–403.
Diabetes Prevention Program Research Group (2002). N. Engl. J. Med. 344, 1342–1350
Shaw, J. E., Hodge, A. M., de Courten, M., Chitson, P., and Zimmet, P. Z. (1999). Diabetologia 42, 1050–1054.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beisswenger, P., Heine, R.J., Leiter, L.A. et al. Prandial glucose regulation in the glucose triad. Endocr 25, 195–202 (2004). https://doi.org/10.1385/ENDO:25:3:195
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:25:3:195